Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3041-3044

  Bali, Alka ^a   Malhotra, Sarika ^b   Dhir, Himjyoti ^b   Kumar, Anil ^a   Sharma, Ajay ^c  

^a PANJAB UNIVERSITY   (India)

^b PUNJABI UNIVERSITY   (India)

^c Zydus Cadila Limited   (India)

Author keywords

1 (Quinolyloxypropyl) 4 aryl piperazines; Atypical antipsychotics; Schizophrenia; Similarity

Indexed keywords

8 HYDROXYQUINOLINE ETHER DERIVATIVE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; KETANSERIN; PIPERAZINE DERIVATIVE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; STEREOTYPY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; MICE; OXYQUINOLINE; SCHIZOPHRENIA; STEREOTYPED BEHAVIOR;

MUS;

EID: 65149105853     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.019     Document Type: Article

References (20)

1. Jibson M.D., Glick I.D., and Tandon R. Focus 2 (2004) 17
2. Seeman P., and Van Tol H.H.M. Trends Pharmacol. Sci. 15 (1994) 264
3. Seeman P. In: Bloom F.E., and Kupfer D.V. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 295
4. Meltzer H.Y. Psychopharmacology 99 (1989) S18
5. Melkersson K., and Dahl M.L. Drugs 64 (2004) 701
6. Schwartz J.T., and Brotman A.W. Drugs 44 (1992) 981
7. Perrone R., Berardi F., Colabufo N.A., Leopolde M., and Tortorella V. J. Med. Chem. 43 (2000) 270
8. Geneste H., Backfisch G., Braje W., Delzer J., Haupt A., Hutchins C.W., King L.L., Lubisch W., Steiner G., Teschendorf H., Unger L., and Wernet W. Bioorg. Med. Chem. Lett. 16 (2006) 658
9. Masaguer F.C., Ravina E., Fontenla J.A., Brea J., Tristan H., and Loza M.I. Eur. J. Med. Chem. 35 (2000) 83
10. Reitz A.B., Bennett D.J., Blum P.S., Codd E.E., Maryanoff C.A., Ortegon M.E., Renji M.J., Scott M.K., Shank R.P., and Vaught J.L. J. Med. Chem. 37 (1994) 1060
11. El-Sayeh H.G., Morganti C., and Adams C.E. Br. J. Psychiatry 189 (2006) 102
12. Xu R., Lever J.R., and Lever S.Z. Bioorg. Med. Chem. Lett. 17 (2007) 2594
13. Cole D.C., Ellingboe J.W., Lennox W.J., Mazandarani H., Smith D.L., Stock J.R., Zhang G., Zhou P., and Schechter L.E. Bioorg. Med. Chem. Lett. 15 (2005) 379
14. Cappeli A., Anzini M., Vomero S., Mennuni L., Makovek F., Doucet E., Hamon M., Bruni G., Romeo M.R., Menziane M.C., Benedetti P.G., and Langer T. J. Med. Chem. 41 (1998) 728
15. Kinkead B., Shahid S., Owens M.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 295 (2000) 67
16. Moore N.C., and Gershan S. Clin. Neuropharmacol. 12 (1989) 167
17. In: Vogel H.G. (Ed). Drug Discovery and Evaluation: Pharmacological Assays. 3rd ed. (2007), Springer 761-762
18. 3OCl: C, 69.5; H, 6.5; N, 10.6. Found: C, 69.01; H, 6.32; N, 10.12. Yield 71.8%.
19. Nikolova N., and Jaworska J. QSAR Comb. Sci. 22 (2003) 1006
20. Supplementary data: Table 5 depicting the values of molecular descriptors for the target compounds and standard drugs.